Botanical health products, positioning and requirements for effective and safe use

Environmental Toxicology and Pharmacology

Volumn 12, Issue 4, 2002, Pages 195-211

  Bast, Aalt ^a   Chandler, R Frank ^b   Choy, Patrick C ^c   Delmulle, Luc M ^d   Gruenwald, Joerg ^e   Halkes, S Bart A ^f   Keller, Konstantin ^g   Koeman, Jan H ^d   Peters, Paul ^h   Przyrembel, Hildegard ⁱ   De Ree, Ellen M ^j   Renwick, Andrew G ^k   Vermeer, Ingrid T M ^j  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b Chandler Herbal Consulting   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

^d Phytopharm Consulting ^*

^e PhytoPharm Consulting   (Germany)

^f UTRECHT UNIVERSITY   (Netherlands)

^g Federal Institute for Drugs and Medical Devices (BfArM)   (Germany)

^h Inspectorate for Health Protection and Veterinary Public Health   (Netherlands)

ⁱ Federal Institute for Health Protection of Consumers and Veterinary Medicine   (Germany)

^j NUMICO RESEARCH   (Netherlands)

^k UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

more..

Author keywords

Botanical health product; Efficacy and safety assessment of botanical products; Herbal medicinal product; Procedure to categorize botanical products; Quality

Indexed keywords

HERBACEOUS AGENT;

ARTICLE; BOTANY; CANADA; CULTURAL ANTHROPOLOGY; DECISION MAKING; DRUG CLASSIFICATION; DRUG CONTROL; DRUG EFFICACY; DRUG LEGISLATION; DRUG QUALITY; DRUG SAFETY; DRUG USE; EPIDEMIOLOGICAL DATA; EUROPE; FOOD ANALYSIS; HERBAL MEDICINE; HISTORY; METHODOLOGY; NORTH AMERICA; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY CONTROL; RISK ASSESSMENT; UNITED STATES;

EID: 18644381183     PISSN: 13826689     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1382-6689(02)00035-2     Document Type: Article

References (62)

1. AESGP, 1998. Herbal Medicinal Products in the European Union. The Association of the European Self-Medication Industry (AESGP), Brussels, pp. 1-145.
2. Ali M., Thomson M. Consumption of a garlic clove a day could be beneficial in preventing thrombosis. Prostaglandins Leukotrienes Essent. Fatty Acids. 53:1995;211-212.
3. Bayne C.W., Donnelly F., Ross M., Habib F.K. Serenoa repens (Permixon): a 5-α-reductase types I and II inhibitor-new evidence in a coculture model of BPH. Prostate. 40:1999;232-241.
4. Belgisch Staatsblad, 1994. Ministrieel Rondschrijven. Richtlijnen Betreffende de Samenstelling van het Registratiedossier van Geneesmiddelen op Basis van Planten. Belgisch Staatsblad.
5. Belgisch Staatsblad, 1997. Koninklijk Besluit van 29 Augustus 1997 Betreffende de Fabricage van en de Handel in Voedingsmiddelen die uit Planten of uit Plantenbereidingen Samengesteld Zijn of Deze Bevatten. Stbl. 21.
6. Belgisch Staatsblad, 1998. Ministerieel Besluit tot Bepaling van de Samenstelling en de Werking van de Commissie van Advies voor Plantenbereidingen. Stbl. 17.
7. Bennett B.C., Hicklin J.R. Use of saw palmetto (Serenoa repens, Arecaceae) in Florida. Econ. Bot. 52:1998;381-393.
8. Benzi G., Ceci A. Herbal medicines in European regulation. Pharmacol. Res. 35:1997;355-362.
9. Blumenthal M., Busse W.R., Goldberg A., The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. 1998;Integrative Medicine, Boston.
10. Blumenthal M., Goldberg A., Brinckmann J. Herbal Medicine. Expanded Commission E Monographs. 2000;Integrative Medicine Communications, Newton.
11. Breu W., Hagenlocher M., Redl K., Tittel G., Stadler F., Wagner H. Anti-inflammatory activity of sabal fruit extracts prepared with supercritical carbon dioxide. In vitro antagonists of cyclooxygenase and 5-lipoxygenase metabolism. Arzneimittelforschung. 42:1992;547-551. (in German).
12. Brothwell D., Brothwell P. Food in Antiquity. 1969;Thames and Hudson, London.
13. Chutani S.K., Bordia A. The effect of fried versus raw garlic on fibrinolytic activity in man. Atherosclerosis. 38:1981;417-421.
14. Commission on Dietary Supplement Labels, 1997. Report of the Commission on Dietary Supplement Labels. Washington, USA.
15. Coppens P., Bijlsma M., Craddock N., Herreman I., Hurt E., Le Bail-Collet Y., Loosen P. Are foods bearing health claims medicinal products. Scand. J. Nutr. 45:2001;140-145.
16. Council of the European Union, 2001. Common Position Adopted by the Council with a View to the Adoption of a Directive of the European Parliament and of the Council on the Approximation of the Laws of the Member States Relating to Food Supplements. Council of the European Union, Brussels.
17. EAS, 2000. Marketing Food Supplements, Fortified and Functional Food in Europe. European Advisory Services, Brussels.
18. EMEA Ad hoc Working Group on Herbal Medicinal Products, 1998. Proposal for a Note for Guidance on Non-Clinical Testing of Herbal Drug Preparations with Long-Term Marketing Experience-Guidance to Facilitate Mutual Recognition and Use of Bibliographic Data (EMEA/HMPWG/11/99)
19. EMEA Ad hoc Working Group on Herbal Medicinal Products, 1999a. Draft Points to Consider on the Evidence of Safety and Efficacy Required for Well-Established Herbal Medicinal Products in Bibliographic Applications (EMEA/HMPWG/23/99). The European Agency for the Evaluation of Medicinal Products, London.
20. EMEA Ad hoc Working Group on Herbal Medicinal Products, 1999b. Report from the ad hoc Working Group on Herbal Medicinal Products (EMEA/HMPWG/25/99). Working Group on Herbal Medicinal Products, London.
21. EMEA Committee for Proprietary Medicinal Products (CPMP) and Committee for Veterinary Medicinal Products (CVMP), 2001a. Note for Guidance on Quality of Herbal Medicinal Products (CPMP/QWP/2819/00) (EMEA/CVMP/814/00). The European Agency for the Evaluation of Medicinal Products, London.
22. EMEA Committee for Proprietary Medicinal Products (CPMP) and Committee for Veterinary Medicinal Products (CVMP), 2001b. Note for Guidance on Specifications: Test Procedures and Acceptance Criteria for Herbal Drugs, Herbal Drug Preparations and Herbal Medicinal Products (CPMP/QWP/2820/00) (EMEA/CVMP/815/00). The European Agency for the Evaluation of Medicinal Products, London.
23. ESCOP 1999. ESCOP Monographs on the medicinal uses of plant drugs. ESCOP, Exeter, England.
24. European Parliament and The Council, 2001. Council Directive 2001/83/EC of the European Parliament and The Council of 6 November 2001 on the Community code relating to medicinal products for human use.
25. FDA, 2000. Guidance for Industry. Botanical Drug Products (Internet at http://www.fda.gov/cder/guidance/index.htm). Rockville, USA.
26. Fernandez-Armesto F. Food, a History. 2001;Macmillan, Oxford.
27. Gadkari J.V., Joshi V.D. Effect of ingestion of raw garlic on serum cholesterol level, clotting time and fibrinolytic activity in normal subjects. J. Postgrad. Med. 37:1991;128-131.
28. Garard I.D. The Story of Food. 1974;The Avi Publishing Company, Inc, Connecticut.
29. Gutierrez M., Garcia de Boto M.J., Cantabrana B., Hidalgo A. Mechanisms involved in the spasmolytic effect of extracts from Sabal serrulata fruit on smooth muscle. Gen. Pharmacol. 27:1996a;171-176.
30. Gutierrez M., Hidalgo A., Cantabrana B. Spasmolytic activity of a lipidic extract from Sabal serrulata fruits: further study of the mechanisms underlying this activity. Planta Med. 62:1996b;507-511.
31. Health Canada, 2001. Building Together; Phase II in Developing a Proposed Regulatory Framework for Natural Health Products. NHPD Public Consultation, Ottawa, Canada.
32. Health Canada, 2002. Standards of evidence for evaluation of safety and claims for Natural Health Products. Draft document for consultation. Natural Health Products Directorate, Ottawa, Canada.
33. Hedrick U.P. Sturtevant's Edible Plants of the World. 1972;Dover Publications Inc, New York.
34. Hertog M.G., Feskens E.J., Hollman P.C., Katan M.B., Kromhout D. Dietary antioxidant flavonoids and risk of coronary heart disease: the zutphen elderly study. Lancet. 342:1993;1007-1011.
35. Katiyar S.K., Mukhtar H. Tea consumption and cancer. World Rev. Nutr. Diet. 79:1996;154-184.
36. Keller K. Legal requirements for the use of phytopharmaceutical drugs in the Federal Republic of Germany. J. Ethnopharmacol. 32:1991;225-229.
37. Keller K. Herbal medicinal products in Germany and Europe: experiences with national and European assessment. Drug Inf. J. 30:1996;933-948.
38. Koscielny J., Klussendorf D., Latza R., Schmitt R., Radtke H., Siegel G., Kiesewetter H. The antiatherosclerotic effect of Allium sativum. Atherosclerosis. 144:1999;237-249.
39. Kraft K. Herbal medicinal products and drug law. Forsch. Komplementarmed. 6:1999;19-23.
40. Lehman A.J., Fitzhugh O.G. 100-fold margin of safety. Assoc. Food Drug Off. USQ Bull. 18:1954;33-35.
41. Mansaray, M., 2000. Herbal remedies - food or medicines? Chem. Ind., 677-678.
42. Renwick A.G., Lazarus N.R. Human variability and noncancer risk assessment - an analysis of the default uncertainty factor. Regul. Toxicol. Pharmacol. 27:1998;3-20.
43. Rivlin R.S. Historical perspective on the use of garlic. J. Nutr. 131:2001;951S-954S.
44. Rosengarten F. The book of spices. 1973;Pyramid Books, New York.
45. Schilcher H. The present state of phytotherapy in Germany. Dtsch. Apoth. Ztg. 138:1998;144-149.
46. Schneider E. Herbs as functional food: regulation-safety-quality assurance. Dtsch. Lebensm. Rundsch. 97:2001;300-305.
47. Silagy C., Neil A. Garlic as a lipid lowering agent - a meta-analysis. J.R. Coll. Phys. London. 28:1994;39-45.
48. Silverman K.C., Naumann B.D., Holder D.J., Dixit R., Faria E.C., Sargent E.V., Gallo M.A. Establishing data-derived adjustment factors from published pharmaceutical clinical trial data. Hum. Ecol. Risk Assess. 5:1999;1059-1089.
49. Staatsblad van het Koninkrijk der Nederlanden, 2001. Besluit van 19 januari 2001, houdende vaststelling van het Warenwetbesluit Kruidenpreparaten. Stbl. 56, 1-5.
50. Steinhoff, B., 1997. Herbal medicines-increasingly preferred. Pharm. Ztg. 142 (49), 38-43 (4412-4417).
51. Swerdlow J.L. Natures Medicine Plants that Heal. 2000;National Geographic Society, Washington.
52. The Standing Committee on Health, 2002. Second Report; Study on Natural Health Products: The Standing Committee on Health. Canada.
53. United States Senate, 1994. Dietary Supplement Health and Education Act of 1994. 103rd Congress, 2nd session. Report 103-410.
54. van Poppel G., Goldbohm R.A. Epidemiologic evidence for beta-carotene and cancer prevention. Am. J. Clin. Nutr. 62:1995;1393S-1402S.
55. Verhoeven D.T., Goldbohm R.A., van Poppel G., Verhagen H., van den Brandt P.A. Epidemiological studies on brassica vegetables and cancer risk. Cancer Epidemiol. Biomarkers Prev. 5:1996;733-748.
56. Vermeire T., Stevenson H., Pieters M.N., Rennen M., Slob W., Hakkert B.C. Assessment factors for human health risk assessment: a discussion paper. Crit. Rev. Toxicol. 29:1999;3439-3490.
57. WHO, 1987. Principles for the safety assessment of food additives and contaminants in food. Environmental Health Criteria, 70. World Health Organisation, Geneva.
58. WHO, 1996. Annex 8. Good Manufacturing Practices: Supplementary Guidelines for the Manufacture of Herbal Medicinal Products. WHO Technical report series, No. 863. World Health Organisation, Geneva, pp. 109-113.
59. WHO, 1998. Regulatory Situation of Herbal Medicines. World Health Organization, Geneva, pp. 1-25.
60. WHO, 1999. WHO Monographs on Selected Medicinal Plants. Volume 1. World Health Organization, Geneva.
61. WHO, 2001. WHO monographs on selected medicinal plants. Volume 2. World Health Organization, Geneva.
62. Wilt T.J., Ishani A., Stark G., MacDonald R., Lau J., Mulrow C. Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. J. Am. Med. Assoc. 280:1998;1604-1609.